4 Stocks Pushing The Health Services Industry Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 21 points (-0.2%) at 12,999 as of Friday, Nov. 30, 2012, 11:49 AM ET. The NYSE advances/declines ratio sits at 1,281 issues advancing vs. 1,584 declining with 138 unchanged.

The Health Services industry currently sits down 0.3% versus the S&P 500, which is down 0.2%. A company within the industry that increased today was Fresenius Medical Care Corporation ( FMS), up 1.1%. On the negative front, top decliners within the industry include Health Management Associates ( HMA), down 2.7%, Brookdale Senior Living ( BKD), down 1.6%, Intuitive Surgical ( ISRG), down 1.1% and DaVita HealthCare Partners ( DVA), down 0.8%.

TheStreet Ratings group would like to highlight 4 stocks pushing the industry higher today:

4. WuXi PharmaTech (Cayman ( WX) is one of the companies pushing the Health Services industry higher today. As of noon trading, WuXi PharmaTech (Cayman is up $0.50 (3.0%) to $16.92 on heavy volume Thus far, 488,873 shares of WuXi PharmaTech (Cayman exchanged hands as compared to its average daily volume of 291,500 shares. The stock has ranged in price between $16.35-$17.08 after having opened the day at $16.50 as compared to the previous trading day's close of $16.42.

Wuxi PharmaTech (Cayman) Inc., through its subsidiaries, operates as a pharmaceutical, biotechnology, and medical device research and development outsourcing company primarily in the People's Republic of China and the United States. WuXi PharmaTech (Cayman has a market cap of $1.1 billion and is part of the health care sector. The company has a P/E ratio of 59.6, above the S&P 500 P/E ratio of 17.7. Shares are up 45.8% year to date as of the close of trading on Thursday. Currently there are 9 analysts that rate WuXi PharmaTech (Cayman a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates WuXi PharmaTech (Cayman as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, attractive valuation levels and growth in earnings per share. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full WuXi PharmaTech (Cayman Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

3. As of noon trading, Mindray Medical International ( MR) is up $0.28 (0.8%) to $33.93 on average volume Thus far, 275,493 shares of Mindray Medical International exchanged hands as compared to its average daily volume of 416,200 shares. The stock has ranged in price between $33.11-$34.00 after having opened the day at $33.82 as compared to the previous trading day's close of $33.65.

Mindray Medical International Limited, through its subsidiary, Shenzhen Mindray, develops, manufactures, and markets medical devices worldwide. It operates in three segments: Patient Monitoring and Life Support Products, In-Vitro Diagnostic Products, and Medical Imaging Systems. Mindray Medical International has a market cap of $3.8 billion and is part of the health care sector. The company has a P/E ratio of 24.6, above the S&P 500 P/E ratio of 17.7. Shares are up 31.2% year to date as of the close of trading on Thursday. Currently there are 6 analysts that rate Mindray Medical International a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Mindray Medical International as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Mindray Medical International Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

2. As of noon trading, Edwards Life ( EW) is up $0.71 (0.8%) to $84.65 on light volume Thus far, 231,554 shares of Edwards Life exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $83.99-$84.93 after having opened the day at $84.41 as compared to the previous trading day's close of $83.94.

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases or critically ill patients worldwide. Edwards Life has a market cap of $9.7 billion and is part of the health care sector. The company has a P/E ratio of 36.8, above the S&P 500 P/E ratio of 17.7. Shares are up 18.8% year to date as of the close of trading on Thursday. Currently there are 9 analysts that rate Edwards Life a buy, 2 analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Edwards Life as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, increase in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Edwards Life Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

1. As of noon trading, St Jude Medical ( STJ) is up $0.40 (1.2%) to $34.09 on heavy volume Thus far, 4.9 million shares of St Jude Medical exchanged hands as compared to its average daily volume of 3.7 million shares. The stock has ranged in price between $33.99-$35.06 after having opened the day at $34.75 as compared to the previous trading day's close of $33.69.

St. Jude Medical, Inc. develops, manufactures, and distributes cardiovascular and implantable neurostimulation medical devices worldwide. It operates in four segments: Cardiac Rhythm Management, Cardiovascular, Atrial Fibrillation, and Neuromodulation. St Jude Medical has a market cap of $10.1 billion and is part of the health care sector. The company has a P/E ratio of 13.8, below the S&P 500 P/E ratio of 17.7. Shares are down 4.1% year to date as of the close of trading on Thursday. Currently there are 13 analysts that rate St Jude Medical a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates St Jude Medical as a buy. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full St Jude Medical Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null

If you liked this article you might like

Don't Miss Today's Strong And Under The Radar Stock: WuXi PharmaTech (WX)

Don't Miss Today's Strong And Under The Radar Stock: WuXi PharmaTech (WX)

WuXi PharmaTech (WX) Showing Signs Of Being Strong And Under The Radar

WuXi PharmaTech (WX) Showing Signs Of Being Strong And Under The Radar

Don't Miss Today's Strong And Under The Radar Stock: WuXi PharmaTech (WX)

Don't Miss Today's Strong And Under The Radar Stock: WuXi PharmaTech (WX)

Strong And Under The Radar Today: WuXi PharmaTech (WX)

Strong And Under The Radar Today: WuXi PharmaTech (WX)

Don't Miss Today's Strong And Under The Radar Stock: WuXi PharmaTech (WX)

Don't Miss Today's Strong And Under The Radar Stock: WuXi PharmaTech (WX)